Cargando…

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

BACKGROUND: The REFINE study examined the efficacy and safety of adding topical corticosteroid therapy to etanercept when stepping down from the initial dose of etanercept to the maintenance dose. Clinical responses were shown to be similar in patients who remained on etanercept 50 mg twice weekly (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papp, K.A., Barber, K., Bissonnette, R., Bourcier, M., Lynde, C.W., Poulin, Y., Shelton, J., Garces, K., Toole, J., Poulin‐Costello, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024053/ https://www.ncbi.nlm.nih.gov/pubmed/25611084 http://dx.doi.org/10.1111/jdv.12934

Ejemplares similares

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)
por: Papp, KA, et al.
Publicado: (2015)

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
por: Gooderham, M.J., et al.
Publicado: (2018)

Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study
por: Thorne, Carter, et al.
Publicado: (2017)

The safety of etanercept for the treatment of plaque psoriasis
por: Papp, Kim A
Publicado: (2007)

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab
por: Ghazawi, Feras M., et al.
Publicado: (2021)

The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis
por: Pope, Janet E, et al.
Publicado: (2014)

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting
por: Papp, K.A., et al.
Publicado: (2022)

Psoriasis Prevalence and Severity by Expert Elicitation
por: Papp, Kim A., et al.
Publicado: (2021)

Etanercept in the treatment of plaque psoriasis
por: Nguyen, Thao U, et al.
Publicado: (2009)

Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology
por: Papp, Kim A., et al.
Publicado: (2021)

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
por: Bessette, Louis, et al.
Publicado: (2017)

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
por: Gottlieb, AB, et al.
Publicado: (2012)

Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis
por: Keystone, Edward C., et al.
Publicado: (2016)

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
por: Ports, WC, et al.
Publicado: (2013)

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies
por: Kimball, A.B., et al.
Publicado: (2019)

Etanercept in the Treatment of Generalized Annular Pustular Psoriasis
por: Lo Schiavo, Ada, et al.
Publicado: (2012)

Etanercept in psoriasis: the evidence of its therapeutic impact
por: Thomson, Andrew
Publicado: (2007)

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis
por: Blauvelt, A., et al.
Publicado: (2017)

Use of etanercept for psoriasis in a liver transplant recipient
por: Madankumar, Reshmi, et al.
Publicado: (2015)

Glomerular filtration rate in patients with psoriasis treated with etanercept
por: Gisondi, Paolo, et al.
Publicado: (2016)

Effects of methotrexate and etanercept treatment in moderate and severe psoriasis
por: Benites, Elizabeth, et al.
Publicado: (2022)

Real-World Experience with Etanercept Therapy and the Switching Pattern among Korean Patients with Psoriasis after Withdrawal of Etanercept
por: Choi, Chong Won, et al.
Publicado: (2019)

Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update
por: Segaert, Siegfried
Publicado: (2009)

Relationship between etanercept and thyroid function in patients with psoriasis vulgaris
por: ROMAN, IULIA IOANA, et al.
Publicado: (2018)

Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports
por: De Simone, Clara, et al.
Publicado: (2016)

Paradoxical SAPHO Syndrome after Etanercept in a Patient with Psoriasis
por: Gimeno-Castillo, Javier., et al.
Publicado: (2022)

Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
por: Papp, Kim A., et al.
Publicado: (2022)

Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO‐INSIGHTFUL study
por: Hong, C‐H., et al.
Publicado: (2017)

Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
por: Papp, Kim A., et al.
Publicado: (2023)

Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
por: van Vollenhoven, Ronald F, et al.
Publicado: (2003)

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
por: Kivelevitch, Dario, et al.
Publicado: (2014)

Long-term safety of etanercept in psoriasis: Retrospective study focused on infections
por: Orsini, Diego, et al.
Publicado: (2016)

Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis
por: Reich, Kristian, et al.
Publicado: (2015)

Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH
por: Poulin, Y, et al.
Publicado: (2014)

Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome
por: Lima, Hermenio, et al.
Publicado: (2017)

A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
por: Colombo, Giorgio L, et al.
Publicado: (2009)

Nodular Vasculitis That Developed during Etanercept (Enbrel) Treatment in a Patient with Psoriasis
por: Park, Seung-Bae, et al.
Publicado: (2015)

Etanercept plus methotrexate: An effective combination therapy for recalcitrant pemphigus vulgaris
por: Andrés, Tirado-Sánchez, et al.
Publicado: (2015)

Health-Related Quality of Life Worsens Disproportionately to Objective Signs of Psoriasis After Withdrawal of Adalimumab Therapy
por: Poulin, Yves, et al.
Publicado: (2014)

The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
por: Livermore, P, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ii2nsgjj47reihml7pddf6gr24